BioMed X has initiated a new joint research group in collaboration with Boehringer Ingelheim at the BioMed X Innovation Center in Heidelberg to investigate myelination deficits of the adolescent brain in connection with the development of schizophrenia. Psychiatric disorders such as schizophrenia emerge as consequence of abnormal brain development and maturation. In schizophrenia, there is evidence that genetic, epigenetic and environmental factors negatively affect the balanced functional m...